Show simple item record

The quantity and quality of worldwide new drug introductions, 1982-2003.

dc.contributor.author Grabowski, Henry G
dc.contributor.author Wang, Y Richard
dc.coverage.spatial United States
dc.date.accessioned 2013-04-23T17:03:00Z
dc.date.issued 2006-03
dc.identifier https://www.ncbi.nlm.nih.gov/pubmed/16522586
dc.identifier 25/2/452
dc.identifier.uri https://hdl.handle.net/10161/6725
dc.description.abstract We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately. Both biotech and orphan products enjoyed tremendous growth, especially for cancer treatment. Country-level analyses for 1993-2003 indicate that U.S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch.
dc.language eng
dc.publisher Health Affairs (Project Hope)
dc.relation.ispartof Health Aff (Millwood)
dc.relation.isversionof 10.1377/hlthaff.25.2.452
dc.subject Biotechnology
dc.subject Drug Industry
dc.subject Drugs, Investigational
dc.subject Europe
dc.subject Global Health
dc.subject Humans
dc.subject Investigational New Drug Application
dc.subject Orphan Drug Production
dc.subject United States
dc.title The quantity and quality of worldwide new drug introductions, 1982-2003.
dc.type Journal article
duke.contributor.id Grabowski, Henry G|0099498
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/16522586
pubs.begin-page 452
pubs.end-page 460
pubs.issue 2
pubs.organisational-group Duke
pubs.organisational-group Economics
pubs.organisational-group Trinity College of Arts & Sciences
pubs.publication-status Published
pubs.volume 25
dc.identifier.eissn 1544-5208


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record